Physician profile
Jerrold L Selzer
NPI 1437191749
$2,639.68
in general payments reported to CMS, 2019-2025
29 companies · $16.17 in 2025
The $16.17 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $560 · 2021: $430 · 2022: $1,053 · 2023: $277 · 2025: $16.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $556.80 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $415.67 | 2019-2023 | Farxiga |
| Pfizer INC. | $202.88 | 2019-2022 | |
| Amarin Pharma, INC. | $172.56 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.74 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $160.02 | 2020-2022 | |
| Amgen INC. | $132.81 | 2019-2023 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $118.04 | 2022-2023 | Mounjaro, Trulicity |
| Kowa Pharmaceuticals America, INC. | $73.41 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $67.28 | 2019-2022 | |
| Abbvie INC. | $64.23 | 2022-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $59.10 | 2022-2025 | Shingrix, Arexvy, Boostrix |
| Arbor Pharmaceuticals, INC. | $51.70 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.06 | 2021-2022 | |
| Radius Health, INC. | $40.22 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.84 | 2020 | |
| Dexcom, INC. | $30.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.39 | 2020-2022 | |
| Allergan, INC. | $27.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.36 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $24.48 | 2023 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $19.11 | 2023 | Rexulti |
| Nevro Corp. | $18.95 | 2023 | Senza |
| Eisai INC. | $18.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.38 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.38 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.89 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $16.49 | 2021 | |
| Valeritas, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrold Selzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.